Key Points
- Major shareholder Jorey Chernett purchased 12,000 Oncology Institute shares at an average price of $6.54, investing $78,480 and increasing their position by 0.11% to 10.66 million shares.
- Oncology Institute shares opened at $6.31 and were reported down 2.2%; the stock has traded between $2.32 and $7.05 over the past year.
- Analyst sentiment remains negative: Weiss Ratings initiated coverage with a “sell (D-)” rating, matching the company’s current consensus “Sell” rating.
Oncology Institute, Inc. (NASDAQ:STLN - Get Free Report) major shareholder Jorey Chernett purchased 12,000 shares of Oncology Institute stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the transaction, the insider directly owned 10,660,858 shares of the company's stock, valued at approximately $69,722,011.32. The trade was a 0.11% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Oncology Institute Stock Down 2.2%
NASDAQ:STLN opened at $6.31 on Tuesday. Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $7.05.
Wall Street Analyst Weigh In
Separately, Weiss Ratings assumed coverage on Oncology Institute in a report on Thursday, August 6th. They set a "sell (d-)" rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Oncology Institute presently has a consensus rating of "Sell".
Read Our Latest Stock Report on Oncology Institute
About Oncology Institute
(
Get Free Report)
Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.
The company's business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
